Age, yrs* | 55.05 ± 9.79 | 52.00 ± 10.49 | 45.00 ± 16.00 |
Female, %** | 78.95 | 71.43 | 83.33 |
Disease duration, yrs* | 10.89 ± 7.43 | 15.79 ± 16.75 | 8.67 ± 6.31 |
Rheumatoid factor and/or ACPA-positive, %** | 89.47 | 85.71 | 66.67 |
Radiographic erosive disease, n (%)** | 10 (52.63) | 9 (64.29) | 3 (50.00) |
Radiographic non-erosive disease, n (%)** | 3 (15.79) | 2 (14.29) | 3 (50.00) |
Radiographic not specified, n (%)** | 6 (31.58) | 3 (21.43) | 0 (0.00) |
Previous DMARD, more than one, n (%)** | 10 (52.63) | 10 (71.42) | 5 (83.33) |
Previous DMARD, one, n (%)** | 4 (21.05) | 1 (7.14) | 1 (16.66) |
Previous DMARD, none or not specified, n (%)** | 5 (26.32) | 3 (21.43) | 0 (0.00) |
Previous biologics, more than one anti-TNF agent, n (%)** | 10 (52.63) | 6 (42.86) | 5 (83.33) |
Previous biologics, one anti-TNF agent, n (%)** | 9 (47.37) | 5 (35.71) | 1 (16.66) |
Previous biologics, IL-1 receptor antagonist, n (%)** | 3 (15.79) | 1 (7.14) | 0 (0.00) |
Previous biologics, none or not specified, n (%)** | 4 (21.05) | 3 (21.43) | 0 (0.00) |
Extraarticular manifestation of RA, n (%)** | 5 (26.32) | 7 (50.00) | 1 (16.66) |
Rheumatoid nodules, n (%)** | 4 (21.05) | 7 (50.00) | 1 (16.66) |